Abstract PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at
high levels in haematological malignancies and solid tumours. The physiological functions …

Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an …

Several tumor-associated antigens (TAAs) were recently identified, that could qualify as
targets for immunotherapy, they could qualify (on RNA-level) for monitoring of tumor load …

The preferentially expressed antigen of melanoma (PRAME) is expressed at high levels in
large fractions of human malignancies, eg, acute myeloid leukemia. Therefore, PRAME is an …

PRAME is a tumor-associated antigen, which belongs to the family of cancer–testis antigens
(CTA). The expression of CTA is mainly restricted to the testis and various tumors. In contrast …

Abstract Background/Aims: The expression of PRAME and its role in hepatocellular
carcinoma (HCC) remain unknown. The aim of this study was to examine the functional role …

We used BAC array-based CGH to detect genomic imbalances in 187 CLL cases.
Submicroscopic deletions of chromosome 22q11 were observed in 28 cases (15%), and the …

Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of
the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain …

Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical
outcomes are disappointing for elderly patients, patients with less fit disease characteristics …

MATERIALS AND METHODS: The pCDNA3-PRAME plasmid and its control were
transfected with the KG-1 cells. The pCDNA3-PRAME transfected KG-1 cells were then …